Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion
Status:
Completed
Trial end date:
2020-01-10
Target enrollment:
Participant gender:
Summary
A total of 80 patients will be randomly allocated into 2 groups, group A and placebo group
using concealed envelope method.Group A patients (n= 40)will receive single dose intravenous
infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
Patients in the placebo group (n=40) will receive as a single-dose of saline (Natriumklorid 9
mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.